Phase II study of oxaliplatin, UFT, and leucovorin in patients with metastatic gastric cancer
- 1 June 2010
- journal article
- Published by Springer Nature in Gastric Cancer
- Vol. 13 (2) , 95-100
Abstract
The present study evaluated the efficacy and safety of oxaliplatin, UFT, and leucovorin in metastatic gastric cancer. Patients received intravenous oxaliplatin 130 mg/m2 on day 1, followed by oral UFT capsules (350 mg/m2 per day) and leucovorin tablets (90 mg/day), every 8 h, for 14 days, in a 3-week cycle. Twenty-three patients (61% with ≥2 metastatic sites), median age of 60 years (range, 39–69 years) were entered. Based on intention-to-treat analysis, one complete response and seven partial responses were found, resulting in an overall response rate (RR) of 35% (95% confidence interval [CI], 16–54), a median time to progression of 4 months (95% CI, 0.5–7.5), and a median overall survival (OS) of 8 months (95% CI, 4.5–11.5). The 1-year survival rate was 26%. Three patients did not complete the first course of 2 weeks; 1 died suddenly on day 16 with fatal lung embolism; 1 had rapid progressive disease and 1 experienced gastric hemorrhage on day 15 — both these patients withdrew. In the 20 patients assessable for toxicity no grade 4 toxicity occurred, grade 3 toxicity consisted of anemia in 1, diarrhea in 2, and neurotoxicity in 3 patients. No hand-foot syndrome (HFS) occurred. Oxaliplatin is an effective drug in gastric cancer, but, as previously reported, its feasibility in combination with capecitabine is hampered due to combined hand-foot-based toxicity. The present phase II study of a combination of oxaliplatin with UFT and leucovorin appears to have efficacy and tolerability comparable to two other drug regimens used in gastric cancer, without the HFS problem.Keywords
This publication has 40 references indexed in Scilit:
- Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancerAnnals of Oncology, 2009
- Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancerNature Reviews Clinical Oncology, 2009
- Capecitabine and Oxaliplatin for Advanced Esophagogastric CancerNew England Journal of Medicine, 2008
- Quality of Life in Operable Colon Cancer Patients Receiving Oral Compared With Intravenous Chemotherapy: Results From National Surgical Adjuvant Breast and Bowel Project Trial C-06Journal of Clinical Oncology, 2007
- An open, multi-centre, phase II clinical trial to evaluate the efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancerBritish Journal of Cancer, 2006
- Palliative chemotherapy for advanced gastric cancerAnnals of Oncology, 2004
- High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7)European Journal of Cancer, 2001
- First demonstration of anti-lymphoma activity of BCL-2 antisense molecule-G3139; Results of phase I/IIA clinical trialEuropean Journal of Cancer, 1997
- Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancerBritish Journal of Cancer, 1995
- The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agentJournal of Chronic Diseases, 1961